Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients

From: Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma

Characteristic Number
Number of patients N = 27 %
Age at enrolment (years)   
 Median 59
 Range 23-80
Gender   
 Male 15 56%
 Female 12 44%
Stage of disease at baseline   
 Stage IV   
 M1a 4 15%
 M1b 4 15%
 M1c 19 70%
Period of time with metastases   
 Median 2.5 months
 Range 0-115 months
LDH   
 Normal (≤333) 14 54%
 High (>333) 4 15%
 Unknown 9 35%
BRAF mutation   
 WT 9 35%
 V600E 11 42%
 V600K 5 19%
 K601E 1 4%
 unknown 1 4%
Treatment (post enrolment)   
 Vemurafenib 12 46%
 Ipilimumab 4 15%
 Dacarbazine 5 19%
 Surgery 4 15%
 Dabrafenib/Trametinib 1 4%
 No treatment 1 4%